Ročníky Psychiatrie

Editorial ............................................................................................................. 1
Program ............................................................................................................. 4
Plenární přednášky
Omezený vliv stresu v depresi: jak antidepresiva fungují a proč nefungují lépe............... 8
Kult velkého pohybu................................................................................................ 8
Co se dá vyčíst z lidského (mého) genomu? ............................................................ 8
Odborná sympozia
Volba léčebné intervence u pacientů s afektivními, psychotickými
a úzkostnými poruchami ......................................................................................... 9
Depotní antipsychotická léčba .................................................................................10
Chronobiologické aspekty u bipolární afektivní poruchy a depresivní poruchy ................12
Antidepresiva v klinické praxi....................................................................................13
Specifické farmakoterapeutické postupy v dětské a dorostové psychiatrii..................... 15
ADHD v dospělosti ...................................................................................................15
Farmakoterapie a její limity v léčbě ADHD v průběhu života......................................... 17
rTMS a její použití v psychiatrii a v algeziologii ..........................................................18
Limity farmakoterapie neuropsychiatrických onemocnění a možnosti jejich překonání .....20
Funkční interakce látek vyvolávajících závislost.......................................................... 21
Epigenom II − epigenom v praxi................................................................................22
Vliv kanabisu na neuropsychologické funkce a mozkovou aktivitu ................................ 24
Obsedantně-kompulzivní porucha (OCD): od nervových buněk k lidskému
pacientovi ................................................................................................................25
Léčba psychofarmaky a společensky tolerované drogy................................................26
Renín-angiotenzín-aldosterónový systém ako cieľ antidepresívnej
a anxiolytickej liečby................................................................................................27
Kardiometabolické riziko u pacientů se schizofrenií a bipolární poruchou ......................29
Setkání s odborníkem
MUDr. Pavel Fridrich: Srovnání péče o duševně nemocné ve Velké Británii a v ČR..........31
Pracovní snídaně ČNPS........................................................................................... 31
Nový výzkum
Preklinický výzkum I...............................................................................................32
Preklinický výzkum II...............................................................................................33
Klinický výzkum......................................................................................................36
Workshopy
Poruchy příjmu potravy – diagnostické a terapeutické spektrum.................................. 38
Diagnostika a léčba bipolární poruchy.......................................................................38
Deset statečných − paranoidní porucha osobnosti ....................................................40
Farmakoterapie v dětské a dorostové psychiatrii .......................................................41
Diagnostika a léčba ADHD v dospělosti ...................................................................41
Farmakoterapie poruch chování u demencí................................................................43
Jak indikovat psychofarmaka podle příznaků individuálního nemocného .......................43
Farmakologické versus nefarmakologické postupy zvládání pocitu vlastní
důležitosti a bezbřehé sebeprezentace pacientů s psychotickými
a nepsychotickými onemocněními ...........................................................................43
Vývěsková sdělení
Preklinické studie ..................................................................................................45
Klinické studie........................................................................................................55
Jmenný rejstřík ......................................................................................................66

CONTENTS

Editorial....................................................................................................................1
Programme...............................................................................................................4
Plenary lectures
The limited role of stress in depression: how antidepressants work
and why they don’t work better...................................................................................8
A great movement cult............................................................................................. 8
What could we tell from human (my) genome?........................................................... 8
Scientific symposia
The choice of therapeutic intervention in patients with affective, psychotic
and anxiety disorders ..............................................................................................9
Depot antipsychotic treatment..................................................................................10
Chronobiological aspects of bipolar disorder and depression........................................12
Antidepressants in clinical practice...........................................................................13
Special pharmacotherapy in child and adolescent psychiatry..................................... 15
Adult ADHD............................................................................................................15
Pharmacotherapy and its limits in the treatment of ADHD as a life-long disorder............17
rTMS and its treatment application in psychiatry and algesiology.................................18
Pharmacotherapy limitations of neuropsychiatric disorders
and their overcoming...............................................................................................20
Functional interactions of drugs developing dependence ........................................... 21
Epigenome II – epigenome in practice .................................................................... 22
The effects of cannabis on neuropsychological functions and brain activity.................. 24
Obsessive-compulsive disorder (OCD): From nerve cells to human patients................ 25
Pharmacotherapy and socially tolerated drugs..........................................................26
Renin-angiotensin-aldosterone system as a target of antidepressant
and anxiolytic therapy............................................................................................27
Cardiometabolic risk in patients with schizophrenia and bipolar disorder...................... 29
MEET THE EXPERT
MUDr. Pavel Fridrich: A comparison of mental health care in Great Britain
and Czech Republic...............................................................................................31
ČNPS BREAKFAST SYMPOSIA.............................................................................31
NEW RESEARCH
Preclinical research I ........................................................................................... 32
Preclinical research II............................................................................................ 33
Clinical research....................................................................................................36
WORKSHOPS
Eating disorders – diagnostic and therapeutic spectrum............................................38
Bipolar disorder – diagnosis and treatment...............................................................38
The Magnificent Ten − Paranoid Personality Disorder.................................................40
Pharmacotherapy in children and adolescents .........................................................41
Adult ADHD – diagnosis and treatment ..................................................................41
Pharmacotherapy of behavioral disturbances associated with dementia...................... 43
The choice of psychotropic drugs according to the symptoms
of individual patients................................................................................................43
Pharmacological versus non-pharmacological approaches to coping with
a self-importance dellusion and limitless self-presentation in psychotic
and non-psychotic patients ...................................................................................43
POSTER SESSIONS
Preclinical studies.................................................................................................45
Clinical studies.....................................................................................................55
NAME INDEX.........................................................................................................66